Eduardo completed his PhD studies in October 2018 in collaboration with Prof Matthew Cooper at the Institute for Molecular Biosciences (IMB). He is currently extending his research within the Neuroinflammation Lab at the School of Biomedical Sciences. His research focuses on the pharmacological targeting of the innate immune response during neurodegeneration.

Researcher biography

Dr. Albornoz is an early career researcher who has training in neuroscience, immunology, and pharmacology. Prior to migrating to Australia, he completed a bachelor in Biochemistry followed by a master's degree in Chile, he then gained experience working in Chile as a research assistant in the Millennium Institute for Immunology and Immunotherapy, focusing on neurodegeneration and the immune response in the context of Multiple Sclerosis. Later, he was awarded a UQ international scholarship to undertake a Ph.D. at the Institute for Molecular Biosciences (IMB), under the supervision of Prof Matt Cooper, his Ph.D. project has assisted in the development of next-generation NLRP3 inflammasome inhibitors, and to validate NLRP3 as a druggable therapeutic target for Parkinson's disease. He completed his Ph.D. in 2019 and continued his post-doctoral research studies under the supervision of Prof Trent Woodruff. A key focus of his current work is testing novel drugs in preclinical models and understanding the role of peripheral innate immune in neurodegenerative diseases including motor neuron disease (amyotrophic lateral sclerosis), Huntington's disease, and Parkinson's disease.